Lean Mass Lower in Survivors of Pediatric Abdominal, Pelvic Tumors
FRIDAY, Aug. 14, 2020 -- Survivors of pediatric abdominal or pelvic tumors have lower lean mass in association with radiation doses and worse metabolic outcomes, according to a study published online Aug. 13 in Cancer Epidemiology, Biomarkers & Prevention.
Carmen L. Wilson, Ph.D., from the St. Jude Children's Research Hospital in Memphis, Tennessee, and colleagues characterized body composition, metabolic impairments, and physical performance among 431 survivors of pediatric abdominal or pelvic tumors.
The researchers found that in men and women, lean mass was lower than values from the National Health and Nutrition Examination Survey (NHANES). Among men and women, higher cumulative abdominal and pelvic radiation doses were associated with lower lean mass. Relative to NHANES, survivors had an increased prevalence of insulin resistance (IR; 40.6 versus 33.8 percent), low high-density lipoprotein (HDL; 28.9 versus 33.5 percent), and high triglycerides (18.4 versus 10.0 percent). Survivors with normal/high lean mass and high fat mass had an increased risk for IR, low HDL, reduced quadriceps strength at 60 degrees/second and 300 degrees/second, and reduced distance covered in the six-minute walk compared with survivors with normal/high lean mass and normal/low fat mass.
"Body composition abnormalities and cardiometabolic impairments are of concern among survivors given that in the general population, these conditions increase the risk of developing life-threatening diseases including cardiovascular disease and type 2 diabetes," Wilson said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: August 2020
Read this next
TUESDAY, Sept. 22, 2020 -- Cancer patients treated one to three months prior to COVID-19 diagnosis and those treated with chemoimmunotherapy have the highest 30-day mortality,...
THURSDAY, Sept. 17, 2020 -- Among adolescents and young adults (AYAs), cancer incidence increased during 2007 to 2016, according to a report published online Sept. 17 in CA: A...
WEDNESDAY, Sept. 16, 2020 -- For men with localized prostate cancer, hemigland high-intensity focused ultrasound (HIFU) ablation is associated with 73 percent two-year survival...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.